Dipipanone

Dipipanone is a synthetic opioid analgesic. It was developed in the 1950s by a team at the pharmaceutical company Hoffmann-La Roche. Dipipanone is chemically related to pethidine (meperidine) and is a member of the 4-phenylpiperidine class of analgesics. It acts as a full agonist at the mu-opioid receptor, similar to morphine, contributing to its pain-relieving effects.

Medically, dipipanone was primarily used for the management of moderate to severe pain. It was available in various formulations, often combined with other medications, most notably cyclizine, under brand names like Diconal. This combination was particularly noted for its use in treating pain associated with cancer and other chronic conditions. However, its use has declined significantly over time due to concerns about its potential for abuse and addiction, as well as the availability of other, potentially safer, opioid analgesics.

Dipipanone is a controlled substance in many countries due to its opioid properties and potential for misuse. It is subject to strict regulations regarding its production, distribution, and prescription. Like other opioids, common side effects include constipation, nausea, drowsiness, and respiratory depression. Dependence and withdrawal symptoms can occur with prolonged use. Its recreational use has been reported, often in combination with other substances, which can increase the risk of adverse effects.